Why Is IMMUNITYBIO INC (IBRX) Stock Moving Today?

Why IBRX stock is up today

ImmunityBio Inc stock rose 8.05% to $8.19 in early trading on Monday. The move followed a recent earnings report that beat estimates and new developments in the company’s cancer treatment pipeline. The stock has also seen a recent price rebound after a multi-day decline.

What Happened

ImmunityBio reported second-quarter adjusted earnings of $0.08 per share, exceeding the estimated loss of $0.09. Revenue for the period totaled $51.24 million, surpassing the projected $49.7 million. The company also received regulatory approval in the UAE for its lead drug for bladder cancer, marking the broadest approval to date. Additionally, the company’s ANKTIVA treatment received UAE approval for non-small cell lung cancer following a trial that showed a median overall survival of 14.6 months in checkpoint-refractory patients. These developments have sparked renewed investor interest.

The company’s founder has also teased a new trial combining Pluvicto’s targeted radiation with an IL-15-based immune treatment. This announcement has added to the momentum, as the stock extended a three-day losing streak before turning upward.

What The Data Shows

Over the last eight sessions, the stock has risen 5.9% from $7.51 to $7.95. The stock has traded between $1.95 and $12.43 over the past 52 weeks and currently has a market capitalization of $8.3 billion. The company remains unprofitable, with a trailing twelve-month earnings per share of -0.99, but revenue has grown by 192.9% in the same period. The stock has a beta of 0.13, indicating low volatility relative to the market. Recent insider transactions show five sales totaling $3.9 million in the last 90 days, with the most recent filing on July 6.

What To Watch

Investors should continue to monitor the company’s upcoming developments in its clinical trials and regulatory approvals. No earnings date is currently scheduled for the near future.